Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Background: advanced-stage non-small cell lung cancer (NSCLC) is characterized by
having limited treatment options and thus a poor prognosis. However, new treatment …

According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Importance Although the efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors forEGFRgene mutation–positive non–small cell lung cancer is well established …

Introduction: Orally administered small molecule kinase inhibitors (KI) are a key class of
targeted anti-cancer medicines that have contributed substantially to improved survival …

Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …

Selecting the dose of a targeted cancer medicine that is most appropriate for a specific
individual is a rational approach to maximize therapeutic outcomes and minimize toxicity …

Interventions: Four cycles of carboplatin and docetaxel chemotherapy reduced the size of
the tumor; however, it increased in size after 8 months, and re-challenge chemotherapy (RC) …

Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior? -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …